



2023-24 Principles of Pediatric Clinical Pharmacology and Therapeutics

October 2023-May 2024 Continuing Medical Education (CME) Customer Satisfaction Questionnaire

Thank you for attending the 2023-24 Principles of Pediatric Clinical Pharmacology and Therapeutics Lecture Series. We are pleased to have been able to offer CME credits this year. As part of the CME process, we request your feedback on the items below. All questions are optional and you may exit the survey at any time.

OMB# 0925-0648 Exp Date: 6/2024

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0648). Do not return the completed form to this address.

Questions? Contact pharmcourse@infinityconferences.com.

1. Rating of Activity

	1=Not at all	2=Very little	3=Moderately	4=Considerably	5=Completely	N/A=Not applicable
To what extent was the overall quality of the instructional process an asset to the activity?	0	0	\circ	0	0	\bigcirc
To what extent did participation in this activity enhance your professional effectiveness?	\bigcirc	0	\circ	0	0	\bigcirc
Will you change your practice in any way as a result of attending this activity?	0	0	0	0	0	0

2. Did you perceive any commercial bias?
Yes
○ No
JOHNS HOPKINS MEDICINE Eunice Kennedy Shriver National Institute of Child Health and Human Development Best Pharmaceuticals for Children Act (BPCA)
2023-24 Principles of Pediatric Clinical Pharmacology and Therapeutics Continuing Medical Education Questionnaire - Please Indicate Yes or Noto the Following Statements
3. The content presented was balanced, evidence-based, demonstrated scientific rigo and was without commercial bias.
○ Yes
○ No
If no, please specify.
4. I was informed about the existence and resolution of relevant financial relationships/conflict of interests of planners and presenters prior to the presentation
○ Yes
○ No
If no, please specify.

5. Speakers who discussed off label, investigational, or alternative uses of products, devices or techniques disclosed this in their presentation.
Yes
○ No
If no, please specify.
JOHNS HOPKINS MEDICINE Eunice Kennedy Shriver National Institute of Child Health and Human Development Best Pharmaceuticals for Children Act (BPCA)
2023-24 Principles of Pediatric Clinical Pharmacology and Therapeutics Continuing Medical Education Questionnaire - Comments
6. What comments or suggestions do you have for the faculty presenter(s)?
7. Are there any other speakers or new topics you would like to have covered in this or a related activity?
8. Do you have additional comments to enhance the utility or impact of the activity?

9. (Physicians Only) May we contact you in several weeks' timessess the usefulness of this CME activity?	ne with a very brief survey to
○ Yes	
○ No	
If yes, please provide your email address.	

Thank you for your feedback! If you have any other comments, please contact us at pharmcourse@infinityconferences.com.